Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.43
+2.9%
$1.25
$1.05
$10.16
$44.84M1.64355,259 shs331,394 shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.59
-1.0%
$7.13
$3.54
$8.25
$176.82M0.8193,787 shs89,000 shs
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
$4.33
+2.1%
$3.17
$1.78
$10.08
$187.14M2.95596,523 shs125,786 shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.28
-3.5%
$3.44
$2.22
$4.13
$162.79M1.29336,143 shs300,286 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
+2.88%+5.93%+7.52%-12.80%-82.13%
Journey Medical Corporation stock logo
DERM
Journey Medical
-1.04%+5.56%+8.90%+1.61%+40.56%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
+2.12%+11.03%+41.04%+106.19%-51.46%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-3.53%-3.53%-0.91%+9.33%-12.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.699 of 5 stars
3.55.00.00.02.73.30.6
Journey Medical Corporation stock logo
DERM
Journey Medical
2.3218 of 5 stars
3.51.00.00.03.31.70.6
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
2.7026 of 5 stars
3.62.00.00.03.31.70.6
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
4.2332 of 5 stars
3.52.00.00.02.64.23.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.00
Buy$17.711,138.76% Upside
Journey Medical Corporation stock logo
DERM
Journey Medical
3.00
Buy$9.5025.16% Upside
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
3.14
Buy$18.50327.25% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00113.41% Upside

Current Analyst Ratings Breakdown

Latest ACRV, PBYI, KYTX, and DERM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00 ➝ $5.00
5/16/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/15/2025
Journey Medical Corporation stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/15/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
5/5/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$6.00
5/4/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
$56.13M3.15N/AN/A$0.91 per share8.34
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
$7.03M26.62N/AN/A$6.17 per share0.70
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.50M0.71$0.85 per share3.85$1.88 per share1.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$80.56M-$2.220.00N/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)
Journey Medical Corporation stock logo
DERM
Journey Medical
-$14.67M-$0.390.00N/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$127.48M-$3.380.00N/AN/AN/A-51.66%-45.92%8/11/2025 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$30.28M$0.774.268.63N/A16.37%49.35%18.25%7/30/2025 (Estimated)

Latest ACRV, PBYI, KYTX, and DERM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.06N/AN/AN/A$14.93 millionN/A
8/11/2025Q2 2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$1.00N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.11N/AN/AN/A$52.00 millionN/A
5/14/2025Q1 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million
5/13/2025Q1 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57-$0.51+$0.06-$0.51N/AN/A
5/13/2025Q1 2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$1.21-$1.03+$0.18-$1.03N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/AN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/A
11.17
11.17
Journey Medical Corporation stock logo
DERM
Journey Medical
1.07
1.34
1.03
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
N/A
7.44
7.44
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.11
1.53
1.43

Institutional Ownership

CompanyInstitutional Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
71.62%
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
18.08%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
11.90%
Journey Medical Corporation stock logo
DERM
Journey Medical
15.03%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
22.00%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
5831.35 million27.62 millionNot Optionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9023.30 million19.80 millionN/A
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
9643.22 million33.71 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million38.07 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acrivon Therapeutics stock logo

Acrivon Therapeutics NASDAQ:ACRV

$1.43 +0.04 (+2.88%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.42 -0.01 (-1.05%)
As of 07/25/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.59 -0.08 (-1.04%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$7.59 0.00 (0.00%)
As of 07/25/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Kyverna Therapeutics stock logo

Kyverna Therapeutics NASDAQ:KYTX

$4.33 +0.09 (+2.12%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$4.33 0.00 (0.00%)
As of 07/25/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.28 -0.12 (-3.53%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$3.27 -0.01 (-0.30%)
As of 07/25/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.